Lupin receives US FDA approval for infection drug

NEW DELHI: Indian pharmaceutical firm Lupin Ltd has received final approval from the US Food and Drug Administration (US FDA) to market a generic version of Valeant Pharmaceuticals International Inc’s Ancobon capsules, the company said. The capsules—flucytosine capsules USP (250 mg and 500mg)—are indicated for the treatment of serious infections caused by certain strains of Candida and Cryptococcus, it added.

Ancobon capsules had sales of $46.6 million in the US, said Lupin, citing IMS Moving Annual Turnover (MAT) data for March 2017.

Share prices of Lupin Ltd on the Bombay Stock Exchange (BSE) were up 3.22% at Rs 1,152.70 per share at 2:26 pm on Monday.